Danish drug giant found to have failed to accurately report spending even after admitting to errors
The pharmaceutical watchdog has reprimanded Wegovy maker Novo Nordisk for failing to correctly disclose dozens of payments to the UK health sector as it sought to boost sales of its slimming drugs.
The Danish drug giant – Europe’s most valuable listed company – systematically misreported, under-reported or did not disclose funding given over seven years to pharmacy firms, obesity charities, training providers, professional bodies and patient groups.
About Author
More Stories
Researchers create AI-based tool that restores age-damaged artworks in hours
‘Earn up to £800 a day’: job scammers using calls or texts to lure victims
Australia has ‘no alternative’ but to embrace AI and seek to be a world leader in the field, industry and science minister says